
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Bal Harbour, Fla. - Genetic updates on neurofibromatosis and tuberous sclerosis and Langerhans cell histiocytosis presentation in the neonatal period were among the topics discussed by Lawrence F. Eichenfield, M.D., clinical professor of pediatrics and medicine (dermatology), University of California, San Diego, at the annual meeting of the Masters of Pediatrics, hosted by the University of Miami School of Medicine.






